6163银河.net163.am(China)APP官网-BinG百科

Zhejiang Yongning Pharmaceutical Co., Ltd., located in Taizhou, Zhejiang, is a pharmaceutical enterprise that mainly engaged in R&D and production of innovative medicines and preparations, is a national high-tech enterprise, an innovative pilot enterprise and a patent demonstration enterprise in Zhejiang Province.

Our company was established initially in 1974, is the first industrial enterprise in Taizhou with annual sales exceeding 100 million CNY, and was restructured into a joint-stock enterprise in 2007 with a registered capital of 161.6319 million CNY and a warehousing tax exceeding 100 million CNY, and is a "large taxpayer in Zhejiang Province". Covering an area of 140,000 square meters, our company has more than 1,300 employees, including 50 masters, 6 doctors, more than 300 professional and technical personnel, and 23 personnel with senior title. We have 5 classes of products, i.e. chemical preparations, chemical and pharmaceutical intermediates, APIs, Chinese patent medicines and health-care products, total of more than 100 products.

Safflower yellow for injection, which is the company's main product, was listed in the national "863" Program, has been awarded a certificate of "National Key & New Product", Zhejiang Province Patent Gold Award, Second Prize of Zhejiang Science and Technology Progress and the first second-class protected variety of Chinese medicine. The planting base for safflower in Xinjiang was rated as "National Demonstration Base for Genuine Medicinal Material (Safflower) with High Quality ". Candesartan cilexetil tablets and Levocetirizine hydrochloride tablets passed the quality and efficacy consistency evaluation, and were both successfully selected in the centralized bidding and procurement of medicines in January 2020. For Candesartan cilexetil tablets, we are the first Chinese manufacturer to pass quality and efficacy consistency evaluation, with No.1 sales volume in domestic market.

All of our products have been granted national GMP certification (new version), some of which have been approved by US FDA, Japanese PMDA and Korean KFDA. Among them, Cefotiam Hydrochloride is approved as a USP reference standard by US Pharmacopeial Convention. At present, we are focusing on a number of new drug projects, one of which is listed in Major National Special Projects. Our company has applied for a total of more than 80 patents, and 50 patents have been authorized so far, including 9 foreign patents (4 US patents). Our company has set up provincial postdoctoral workstation, R&D institutions in many colleges & universities in Beijing, Shanghai, Nanjing etc., and has been classified as "Provincial High-Tech Enterprise Research & Development Center".